Eicosapentaenoic acid used to treat cachexia
AssigneeCancer Research Campaign Technology Limited
InventorsMichael J. Tisdale, Susan A. Beck
Life of this patent
Estimating the term…
Abstract
The use of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid or EPA, preferably substantially free of any other polyunsaturated fatty acids, is disclosed for making up medical preparations or compositions for the treatment of cachexia by inhibiting lipolytic activity of biologically active lipolytic agents present in body fluids and the activity of the enzyme guanidinobenzoatase, as well as for reducing abnormal cAMP levels in cells of adipose tissue in mammals, produced by lipolytic or fat mobilizing substances.
Claims4
A method for treating cancer cachexia in a mammal by inhibiting lipolytic activity of lipolytic factors which comprises administering to said mammal in need of such treatment, an effective amount of 5,8,11,14,17-eicosapentaenoic acid or a pharmaceutically acceptable salt or ester thereof;
- without the primary aim of said method being the treatment of cancer.
Dependencies are inferred from the claim text.